{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=131I-MIBG", "query": { "intervention": "131I-MIBG" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 36, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=131I-MIBG&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T01:57:58.878Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00083135", "title": "N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "iobenguane I 131", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "New Approaches to Neuroblastoma Therapy Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 18, "start_date": "2004-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-09-10T01:57:58.878Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083135" }, { "nct_id": "NCT01448083", "title": "Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neuroendocrine Tumor" ], "interventions": [ { "name": "Standard of care diagnostic MIBG scan for neuroendocrine tumor diagnosis.", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Nuclear Medicine Consultants, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2011-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-09-18", "last_synced_at": "2026-09-10T01:57:58.878Z", "location_count": 1, "location_summary": "Kenner, Louisiana", "locations": [ { "city": "Kenner", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01448083" }, { "nct_id": "NCT01377532", "title": "Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Pheochromocytoma", "Paraganglioma" ], "interventions": [ { "name": "131 I-Metaiodobenzylguanidine (131 I-MIBG)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2020-05-06", "last_synced_at": "2026-09-10T01:57:58.878Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01377532" }, { "nct_id": "NCT01019850", "title": "N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Vorinostat", "type": "DRUG" }, { "name": "131- I Metaiodobenzylguanidine", "type": "RADIATION" }, { "name": "Peripheral Blood Stem Cell Infusion", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "New Approaches to Neuroblastoma Therapy Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 27, "start_date": "2010-03", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2023-04-10", "last_synced_at": "2026-09-10T01:57:58.878Z", "location_count": 12, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01019850" }, { "nct_id": "NCT03126916", "title": "Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ganglioneuroblastoma", "Ganglioneuroblastoma, Nodular", "Neuroblastoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dexrazoxane Hydrochloride", "type": "DRUG" }, { "name": "Dinutuximab", "type": "BIOLOGICAL" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Iobenguane I-123", "type": "RADIATION" }, { "name": "Iobenguane I-131", "type": "RADIATION" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Melphalan Hydrochloride", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "365 Days", "maximum_age": "30 Years", "sex": "ALL", "summary": "365 Days to 30 Years" }, "enrollment_count": 750, "start_date": "2018-05-14", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-10T01:57:58.878Z", "location_count": 152, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03126916" }, { "nct_id": "NCT00874614", "title": "A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pheochromocytoma", "Paraganglioma" ], "interventions": [ { "name": "Ultratrace® Iobenguane I131", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Molecular Insight Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 74, "start_date": "2009-06-04", "completion_date": "2021-02", "has_results": true, "last_update_posted_date": "2020-02-20", "last_synced_at": "2026-09-10T01:57:58.878Z", "location_count": 10, "location_summary": "San Francisco, California • Miami, Florida • Iowa City, Iowa + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00874614" }, { "nct_id": "NCT01313936", "title": "High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Metaiodobenzylguanidine (MIBG)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 32, "start_date": "2011-03", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2019-04-29", "last_synced_at": "2026-09-10T01:57:58.878Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01313936" }, { "nct_id": "NCT06000787", "title": "MCT for the Harvard/UCSF ROBIN Center", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Glioma, Childhood Brainstem", "Neuroblastoma" ], "interventions": [ { "name": "External beam radiotherapy", "type": "RADIATION" }, { "name": "131I-Metaiodobenzylguanidine (MIBG)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 47, "start_date": "2023-09-19", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2025-02-17", "last_synced_at": "2026-09-10T01:57:58.878Z", "location_count": 2, "location_summary": "San Francisco, California • Boston, Massachusetts", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06000787" }, { "nct_id": "NCT00509353", "title": "N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "iobenguane I 131", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "New Approaches to Neuroblastoma Therapy Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 26, "start_date": "2007-01", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-09-10T01:57:58.878Z", "location_count": 12, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509353" }, { "nct_id": "NCT01413503", "title": "A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pheochromocytoma", "Paraganglioma" ], "interventions": [ { "name": "131I-MIBG", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 50, "start_date": "1991-05", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2018-09-18", "last_synced_at": "2026-09-10T01:57:58.878Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01413503" } ] }